Insmed (NASDAQ:INSM) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Insmed (NASDAQ:INSM) had its price target raised by research analysts at The Goldman Sachs Group from $225.00 to $258.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target indicates a potential upside of 28.57% from the stock’s previous close.

INSM has been the subject of a number of other reports. William Blair began coverage on shares of Insmed in a research note on Wednesday, August 20th. They set an “outperform” rating for the company. Mizuho boosted their target price on Insmed from $196.00 to $256.00 and gave the company an “outperform” rating in a research report on Monday, December 1st. Jefferies Financial Group set a $269.00 price target on Insmed in a report on Wednesday, December 10th. UBS Group raised their price target on Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. boosted their price objective on Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $200.89.

Insmed Trading Up 1.9%

Shares of NASDAQ INSM opened at $200.67 on Monday. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The business’s 50 day moving average is $186.64 and its two-hundred day moving average is $141.74. The stock has a market capitalization of $42.80 billion, a P/E ratio of -32.42 and a beta of 1.01.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.Insmed’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.27) EPS. As a group, research analysts expect that Insmed will post -4.56 EPS for the current year.

Insider Transactions at Insmed

In other Insmed news, Director Leo Lee sold 75,000 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the transaction, the director directly owned 54,677 shares in the company, valued at $10,711,224.30. This trade represents a 57.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Elizabeth M. Anderson sold 10,000 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $195.87, for a total value of $1,958,700.00. Following the completion of the sale, the director owned 63,729 shares of the company’s stock, valued at $12,482,599.23. This represents a 13.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 147,130 shares of company stock worth $28,480,051 in the last ninety days. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC raised its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares in the last quarter. ORG Partners LLC boosted its stake in shares of Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares in the last quarter. Hilltop National Bank purchased a new position in Insmed during the second quarter valued at approximately $28,000. Stone House Investment Management LLC bought a new position in Insmed in the third quarter worth approximately $29,000. Finally, SBI Securities Co. Ltd. lifted its holdings in Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 166 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.